On 15 June, the Food and Emergency Administration raised Drug Use Authorization hydroxychloroquine and chloroquine in COVID-19 treatment, noting that a review of new information on the drugs and the appreciation shown by the data available to date, “is no longer reasonable, that the oral formulations to believe [hydroxychloroquine] and [chloroquine] may in COVID-19 treatment to be effective, but it makes sense to believe the known benefits and potential of these products, the known and potential risks predominate. “in one study published in the New England Journal of medicine by a Columbia University team led scientists have found that people infected with COVID-19 is not fare better with hydroxychloroquine compared with those who did not receive the drug. The study released Thursday to investigate the largest ever on the drug, which is approved by the US Food and Drug Administration for the treatment of malaria, and some autoimmune diseases, such as treatment for COVID-19 Dr. Neil Schluger, Head of the Pulmonary Department, allergy and Critical Care Medicine at Columbia, and his team studied more than 1,300 patients admitted to New York Presbyterian Hospital-Columbia University medical Center Irving COVID-19 Some hydroxychloroquine received on an off-label basis, a practice that doctors may prescribe a drug that has been approved for a disease to treat another – in this case COVID-19 approximately 60% of patients received hydroxychloroquine for about five days. They did not show lower rate fans need or a lower risk of dying during the study than people not get the drug. “We do not believe at this point because all the evidence that is reasonable to regularly give patients this drug,” says Schluger. “We do not see the reasons for this have to do.” To receive the drug or a placebo during the study and compare their results, the large number of patients involved suggests the results are determined they did not randomly assign people. Based on the results, says Schluger in his hospital doctors have already changed their advice for treatment is used on hydroxychloroquine COVID-19. “Our leadership had suggested giving early hydroxychloroquine for patients admitted to hospital, and update that leadership to remove this proposal,” he says. The hydroxychloroquine original support came largely from a small study conducted in France, suggested that people receiving the drug did better than those who do not get it. In the United States, President Trump has also expressed interest in the drug as a possible way to control the growing pandemic. But Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases and a member of the White House Task Force Trump Crown, asked for caution and recommended more rigorous studies and data on the effect of the drug on 19-COVID However Schluger says the urgency to help patients in the midst of a pandemic, many doctors and hospitals led dock as potentially effective therapy for hydroxychloroquine. “Physicians see patients dying at an incredible price, and want to do something to try to help them,” he says. “But I think the history of medicine shows us some insights and many, many, many of them are totally wrong.” In a survey of health institutions Sermo survey conducted, 55% of physicians worldwide who were surveyed reported using hydroxychloroquine. Only 29%, however, as very safe – the drug at higher risk of associated cardiac arrhythmias. The findings are likely to change as physicians to hospitalized patients who are seriously ill. But Schluger says it is still possible that hydroxychloroquine may play a role in controlling COVID-19, perhaps as a way to prevent infection in people who are exposed to a high risk of virus, such as health care workers, other studies investigating this possibility. “It ‘s very important for us to know which treatments work and which do not, the patient should be allowed to be offered in a clinical trial,” says Schluger. “It ‘s probably the best thing you can do for themselves and for society as a whole, we really think the answers can get quickly to identify treatments that work and reject the treatments do not work.”
It fails for hydroxychloroquine help patients largest Crown drug study to date
